Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Discovery Platform
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Agreement
Healx Partners with Sanofi To Explore Rare Diseases with AI Drug Discovery
Details : Under the agreement, Sanofi will provide data related to a late stage discontinued asset to identify new disease indications using Healnet, Healx’s AI-driven drug discovery platform.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 13, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Discovery Platform
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Discovery Platform
Sponsor : Nippon Shinyaku
Deal Size : Undisclosed
Deal Type : Collaboration
MiNA Therapeutics Collaborates with Nippon Shinyaku On RNAa Therapies
Details : MiNA Therapeutics will use its RNAa algorithm and platform to identify RNAa molecules targeting rare CNS genetic diseases under the collaboration.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 04, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Discovery Platform
Sponsor : Nippon Shinyaku
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Discovery Platform
Sponsor : GSK
Deal Size : $1,150.0 million
Deal Type : Collaboration
Details : The collaboration will combine Adrestia’s world leading, synthetic viability platform with GSK’s deep scientific expertise in human genetics, functional genomics, screening, and bioinformatics.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 18, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Discovery Platform
Sponsor : GSK
Deal Size : $1,150.0 million
Deal Type : Collaboration